30
total announcements
SUPRIYA.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹7,039 Cr
P/E (TTM)
35.5
P/E (Forward)
22.5
EPS (TTM)
₹24.65
52W Low
₹545.50
52W High
₹1,085.00
Dividend Yield
0.11%
Beta
0.63
Price / Book
5.9
Debt / Equity
0.5
Revenue (TTM)
₹873 Cr
Gross Margin
68.06%
Operating Margin
21.40%
Supriya Lifescience Ltd
Supriya Lifescience Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with a total income from operations of ₹4,791.67 crore and a net profit of ₹1,184 crore.
Supriya Lifescience Ltd
Supriya Lifescience Ltd reported a 31% YoY revenue growth in Q1 FY27, with revenue of Rs 189.75 crore, and a PAT of Rs 24.04 crore. The company's EBITDA margin declined to 25.0% in Q1 FY27 from 35.6% in Q1 FY26.
Supriya Lifescience Ltd
Supriya Lifescience Ltd has released its Q1 FY27 investor presentation, showcasing a 31% YoY increase in revenue, 8% YoY increase in EBITDA, and 14% YoY increase in PBT. The company's PAT has seen a 31% YoY growth. The presentation highlights the company's business mix revenue contribution by region and therapy, with a focus on the top therapeutic areas.
Supriya Lifescience Ltd
Supriya Lifescience Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at ₹1,897.47 crore, ₹2,765.28 crore, ₹1,450.74 crore, and ₹8,278.01 crore for the respective periods.
Supriya Lifescience Ltd
Supriya Lifescience Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at ₹1,897.47 crore.
Supriya Lifescience Ltd
Supriya Lifescience Ltd has announced an earnings call to discuss its unaudited financial results for the quarter ended June 30, 2026. The call is scheduled for August 14, 2026, at 11:00 A.M. IST. The company has also provided details for pre-registration and dial-in for the call.
Supriya Lifescience Ltd
Supriya Lifescience Ltd has scheduled a board meeting on August 13, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The trading window for dealing in the company's securities by designated persons and their immediate relatives will be closed from July 1, 2026, till 48 hours after the declaration of the unaudited financial results.
Supriya Lifescience Ltd
Supriya Lifescience Ltd has announced the publication of a postal ballot notice in newspapers, as per the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice relates to the distribution of income under the Kotak Arbitrage Fund and the record date for the same is July 24, 2026.
Supriya Lifescience Ltd
Supriya Lifescience Ltd has announced a postal ballot notice for the re-appointment of Mr. Balasaheb Sawant as Whole Time Director and Special Key Managerial Personnel for a term of three consecutive years.
Supriya Lifescience Ltd
Supriya Lifescience Ltd issued an email communication to its shareholders detailing the tax deduction at source (TDS) provisions applicable to the final dividend of Re. 1.00/- per equity share for FY2025-26, which was recommended by the board. The communication explains that dividends are taxable in the hands of shareholders and the company will deduct TDS based on residential status and submitted documents. It outlines applicable TDS rates for resident shareholders, including potential exemptions for individuals providing Form 15G/15H if the total dividend is under Rs. 10,000, and emphasizes the need for a valid and operative PAN linked with Aadhaar to ensure appropriate tax deduction.